department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Parlodel · pharmadog

pharmadog
drugs
Parlodel

drug

patient view →

bromocriptine mesylate

Marketedupdated 2mo ago

by Validus Pharmaceuticals LLC

Approved

community read0 votes

indications

investigational

Parkinson's DiseaseType 2 Diabetes

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

brand

Parlodel

generic

bromocriptine mesylate

indication

Amenorrhea

phase

marketed

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Data sources

ClinicalTrials.gov

last refreshed 56m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

Patent cliff

source: FDA Orange Book

first barrier falls

Jun 7, 2030

~3.9 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (13)

Apr 30, 2032method-of-use (U-2886)US 10688094
Apr 30, 2032method-of-use (U-3122)US 11000522
Apr 30, 2032method-of-use (U-4018)US 11666567
Apr 30, 2032formulationUS 8431155
Apr 30, 2032formulationUS 8613947
Apr 30, 2032formulationUS 9192576
Apr 30, 2032formulationUS 9522117
Apr 30, 2032formulationUS 9700555
Apr 30, 2032method-of-use (U-2389)US 9993474
Jun 7, 2030method-of-use (U-2934)US 106881553.9y
Jun 7, 2030formulationUS 88777083.9y
Jun 7, 2030method-of-use (U-2116)US 93520253.9y
Jun 7, 2030method-of-use (U-2283)US 98954223.9y

🐶 often sniffed alongside

top 2

companyZydus Lifesciences Ltd2 co-mentions · 1 sources
tagRecall2 co-mentions · 1 sources

Trials studying bromocriptine mesylate

phase3A Phase III Clinical Study of Cabergoline Tablets Compared With Bromocriptine Mesylate Tabletsrecruitingn=382
phase1Fed Study of (Parlodel®) Bromocriptine Mesylate Capsules 5 mgcompletedn=120
phase1Fed Study of (Parlodel®) 2.5 mg Bromocriptine Mesylate Tabletscompletedn=119